Additional studies showed that aspirin reverses hyperglycemia, hyperinsulinemia, and dyslipidemia by inhibiting the activity of NF-κB and its upstream activator IKK-β in obese rodents (Yuan et al., 2001; Sun et al., 2011; Bako et al., 2019). This evidence concerns the gene NFKB1 and metabolic syndrome.